Clinical Trials on Low Risk Myelodysplastic Syndrome
Total 4380 results
-
GWT-TUD GmbHAmsterdam UMC, location VUmc; BerGenBio ASA; Groupe Francophone des MyelodysplasiesCompletedAcute Myeloid Leukemia | High-risk Myelodysplastic Syndrome | Low-risk Myelodysplastic SyndromeGermany, Netherlands, France
-
Forma Therapeutics, Inc.RecruitingVery Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-RUnited States, France, Canada, Germany
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaboratorsNot yet recruitingLow Risk Myelodysplastic SyndromesSpain, Poland, Italy, Germany, France
-
Rigel PharmaceuticalsRecruitingLow Risk Myelodysplastic SyndromesUnited States
-
Novartis PharmaceuticalsCompletedLow and Int 1-risk Myelodysplastic SyndromeGermany, Canada, Korea, Republic of, Sweden, Spain, China, Argentina, Italy, United Kingdom, Algeria
-
Silence Therapeutics plcCompletedNon-transfusion-dependent Thalassemia | Low Risk Myelodysplastic Syndrome | Very-Low Risk Myelodysplastic SyndromeThailand, Israel, Jordan, United Kingdom, Germany, Italy, Malaysia
-
Celgene CorporationCompletedLow- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMyelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | IPSS Risk Category Intermediate-1United States
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.CompletedPreviously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic SyndromeUnited States
-
Assistance Publique - Hôpitaux de ParisUnknownInfection | Risk Factors | Myelodysplastic Syndrome (MDS) | IPSS High RiskFrance
-
ALX Oncology Inc.Active, not recruitingHigher Risk Myelodysplastic SyndromesKorea, Republic of, United States, Spain
-
AkesoRecruitingHigher-risk Myelodysplastic SyndromesUnited States, China
-
Bristol-Myers SquibbActive, not recruitingLower-risk Myelodysplastic SyndromesJapan
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHigh Risk Myelodysplastic SyndromeUnited States
-
Jasper Therapeutics, Inc.Recruiting
-
Silence Therapeutics plcWithdrawnNon-transfusion-dependent Thalassemia | Low Risk Myelodysplastic SyndromeUnited Kingdom, Bulgaria
-
Otsuka Pharmaceutical Co., Ltd.Active, not recruitingLower-risk MyelodysplasticJapan
-
Schrödinger, Inc.RecruitingAcute Myeloid Leukemia | High-Risk and Very High-Risk Myelodysplastic SyndromesUnited States
-
Central Hospital, Nancy, FranceInserm U954 - N-GERE (Nutrition, Genetics and Exposition to Environmental...UnknownHigh-risk Myelodysplastic Syndromes With Excess BlastsFrance
-
Novartis PharmaceuticalsTerminated
-
FibroGenAstraZeneca; Astellas Pharma IncTerminatedPrimary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Mixed Phenotype Acute LeukemiaUnited States
-
Massachusetts General HospitalDana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and...TerminatedMyelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); CelgeneRecruitingAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome With Excess Blasts | IDH2 Gene Mutation | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 20-30 Percent of Bone Marrow Nucleated CellsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Recurrent Acute Biphenotypic Leukemia | Blasts 20 Percent or More of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk...United States
-
Novartis PharmaceuticalsActive, not recruitingAcute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)Spain, Singapore, Australia, Germany, Italy, Finland, United States
-
University of UlmTerminatedAcute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)Germany
-
Ostfold Hospital TrustUniversity of TromsoCompletedLow Risk Birth; Births With Low Risk FactorNorway
-
Institute of Hematology & Blood Diseases Hospital...Beijing Health Alliance Charitable FoundationRecruitingLower Risk MDS Per IPSS-RChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic SyndromeUnited States
-
Ryvu Therapeutics SAActive, not recruitingAcute Myeloid Leukemia | High-risk Myelodysplastic SyndromeUnited States, Poland
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedAcute Myeloid Leukemia | High Risk Myelodysplastic SyndromeUnited States
-
University of BirminghamJazz Pharmaceuticals; Adienne SA; IMPACT (funded by NHS Blood & Transplant, Anthony...Active, not recruitingAcute Myeloid Leukaemia | High-risk Myelodysplastic SyndromeUnited Kingdom
-
Masonic Cancer Center, University of MinnesotaCompletedAcute Myeloid Leukemia | Higher Risk Myelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 10-19 Percent of Bone Marrow Nucleated Cells and other conditionsUnited States
-
Remix TherapeuticsRecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Myeloid Leukemia Refractory | Higher Risk Myelodysplastic SyndromesUnited States
-
Cardiff UniversityExperimental Cancer Medicine Centres; Leukaemia & Lymphoma Research GroupCompletedHigh Risk Myelodysplastic Syndrome | Acute Myeloid LeukaemiaUnited Kingdom
-
The First Affiliated Hospital of Soochow UniversityUnknownHigher-risk Myelodysplastic Syndrome | Relapsed /Refractory Acute Myeloid Leukemia
-
Ryvu Therapeutics SARecruitingAcute Myeloid Leukemia (AML) | High-risk Myelodysplastic SyndromeItaly, Poland
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Celgene CorporationTerminatedMyelodysplastic Syndrome | MDS | Low to Intermediate-1 MDS | Non-deletion 5qUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic SyndromeUnited States
-
University of UlmRecruitingAcute Myeloid Leukemia (AML) | Higher Risk Myelodysplastic Syndromes (MDS With Excess Blasts 2)Austria, Germany
-
Ascentage Pharma Group Inc.RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | AML | MDS | CMML | High-risk Myelodysplastic SyndromeUnited States
-
AmgenCompletedChronic Myelomonocytic Leukemia | Higher Risk Myelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterAriad PharmaceuticalsWithdrawnLeukemia | FLT3-Mutated Acute Myeloid Leukemia | FLT3-Mutated High-Risk Myelodysplastic Syndrome
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blasts More Than 10 Percent of Bone Marrow Nucleated CellsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterRecruitingAcute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome and other conditionsUnited States